BACKGROUND: This prospective study evaluated the relationship between arthralgia and compliance during the first year of adjuvant anastrozole therapy in postmenopausal women with hormone receptor-positive early breast cancer. PATIENTS AND METHODS: COMPliance and Arthralgia in Clinical Therapy (COMPACT) was an open-label, multicenter, noninterventional study conducted in Germany. Patients had started adjuvant anastrozole 3-6 months before the study start. The primary end points were arthralgia, compliance, and the relationship between compliance and arthralgia, assessed at specific time points. RESULTS: Overall, 1916 patients received upfront anastrozole. Mean arthralgia scores were increased from baseline at each visit up to 9 months. Compliance with anastrozole therapy gradually decreased over time from baseline to 9 months (P<0.001). At 9 months, investigators estimated that >95% of patients were compliant versus patient reports of <70%. There was a significant association between arthralgia mean scores and noncompliance at 6 months (P<0.0001), 9 months (P<0.0001), and overall (P<0.0001). Over time, new events or impairment of existing arthralgias were reported in 14% (3 months), 11% (6 months), and 9% (9 months) of patients. CONCLUSION: Arthralgia is important in the clinical management of women with early breast cancer and may contribute to noncompliance and clinical outcomes. CLINICALTRIALSGOV IDENTIFIER: NCT00857012.
BACKGROUND: This prospective study evaluated the relationship between arthralgia and compliance during the first year of adjuvant anastrozole therapy in postmenopausal women with hormone receptor-positive early breast cancer. PATIENTS AND METHODS: COMPliance and Arthralgia in Clinical Therapy (COMPACT) was an open-label, multicenter, noninterventional study conducted in Germany. Patients had started adjuvant anastrozole 3-6 months before the study start. The primary end points were arthralgia, compliance, and the relationship between compliance and arthralgia, assessed at specific time points. RESULTS: Overall, 1916 patients received upfront anastrozole. Mean arthralgia scores were increased from baseline at each visit up to 9 months. Compliance with anastrozole therapy gradually decreased over time from baseline to 9 months (P<0.001). At 9 months, investigators estimated that >95% of patients were compliant versus patient reports of <70%. There was a significant association between arthralgia mean scores and noncompliance at 6 months (P<0.0001), 9 months (P<0.0001), and overall (P<0.0001). Over time, new events or impairment of existing arthralgias were reported in 14% (3 months), 11% (6 months), and 9% (9 months) of patients. CONCLUSION: Arthralgia is important in the clinical management of women with early breast cancer and may contribute to noncompliance and clinical outcomes. CLINICALTRIALSGOV IDENTIFIER: NCT00857012.
Entities:
Keywords:
anastrozole; aromatase inhibitors; arthralgia; breast neoplasms; patient compliance
Authors: P A Fasching; T Fehm; S Kellner; J de Waal; M Rezai; B Baier; G Baake; H-C Kolberg; M Guggenberger; M Warm; N Harbeck; R Würstlein; J-U Deuker; P Dall; B Richter; G Wachsmann; C Brucker; J W Siebers; N Fersis; T Kuhn; C Wolf; H-W Vollert; G-P Breitbach; W Janni; R Landthaler; A Kohls; D Rezek; T Noesslet; G Fischer; S Henschen; T Praetz; V Heyl; T Kühn; T Krauß; C Thomssen; S Kümmel; A Hohn; H Tesch; C Mundhenke; A Hein; C Rauh; C M Bayer; A Jacob; K Schmidt; E Belleville; P Hadji; D Wallwiener; E-M Grischke; M W Beckmann; S Y Brucker Journal: Geburtshilfe Frauenheilkd Date: 2014-12 Impact factor: 2.915
Authors: Alexander Scherrer; Ilka Schwidde; Andreas Dinges; Patrick Rüdiger; Sherko Kümmel; Karl-Heinz Küfer Journal: Health Care Manag Sci Date: 2014-10-15
Authors: Daniel L Hertz; Julie A Douglas; Robert M Miller; Kelley M Kidwell; Christina L Gersch; Zeruesenay Desta; Anna Maria Storniolo; Vered Stearns; Todd C Skaar; Daniel F Hayes; N Lynn Henry; James M Rae Journal: Support Care Cancer Date: 2022-07-01 Impact factor: 3.359
Authors: Daniel L Hertz; Karen Lisa Smith; Yuhua Zong; Christina L Gersch; Andrea M Pesch; Jennifer Lehman; Amanda L Blackford; N Lynn Henry; Kelley M Kidwell; James M Rae; Vered Stearns Journal: Front Genet Date: 2021-06-15 Impact factor: 4.599